MedWatch

Coloplast CEO on FDA ban: "We are disappointed"

CEO in Coloplast Kristian Villumsen is disappointed over FDA's decision to ban the company's transvaginal synthetic mesh product although the prohibition only has marginal impact on Coloplast's revenue. However, analyst calls the case "bad news" for the company.

Kristian Villumsen, CEO in Coloplast. | Foto: Coloplast PR

Coloplast is disappointed with the US Food and Drug Agency's decision to remove the company's surgical transvaginal mesh Restorelle DirectFix Anterior as a treatment option for women with pelvic organ prolapse.

"We are disappointed with the FDA’s decision because it reduces the treatment options for women with pelvic organ prolapse," says CEO Kristian Villumsen in a press release.

Læs hele artiklen

Få 14 dages fri adgang.
Det kræver intet kreditkort.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Relaterede

Seneste nyt

Ledige job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier